T. Bauer

Manish B. Patel, A. Iafrate, A. Drilon, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

J. Schellens, Sunil Sharma, A. Naing, 2020, Journal for ImmunoTherapy of Cancer.

A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.

P. LoRusso, J. Infante, J. Eder, 2015 .

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

J. Ajani, J. Mayordomo, F. Meric-Bernstam, 2018 .

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Suzanne F. Jones, R. Kurzrock, F. Janku, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

C. Rudin, R. Govindan, R. Salgia, 2015 .

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

M. Zauderer, A. Varghese, J. Bendell, 2021, Investigational New Drugs.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

A. Shaw, T. Mok, E. Felip, 2020, The New England journal of medicine.

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

G. Shapiro, T. Yap, R. Jeselsohn, 2022, JCO precision oncology.

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

A. Shaw, Melissa L. Johnson, E. Felip, 2020, Targeted Oncology.

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

E. Jonasch, T. Choueiri, M. Michaelson, 2021, Nature Medicine.

Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings

Suzanne F. Jones, Melissa L. Johnson, L. Hart, 2016 .

PHASE I STUDIES

A. Muehler, K. Venkatakrishnan, J. Nemunaitis, 2018 .

Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors

B. Linghu, C. Drake, J. Bendell, 2019, Clinical Trials.

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

J. Reeves, B. Somer, N. Vogelzang, 2020, Clinical genitourinary cancer.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

E. Lam, B. Somer, N. Vogelzang, 2020, Clinical genitourinary cancer.

Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.

A. Shaw, S. Ou, Gregory Riely, 2018 .

Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).

Y. Bang, M. Schuler, D. Hong, 2016 .

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

K. Papadopoulos, J. Infante, A. Naing, 2019, The Lancet. Oncology.

Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

E. Plimack, M. Voss, B. Rini, 2018, Journal of Immunotherapy for Cancer.

Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.

D. Nam, Y. Bang, I. Braña, 2014 .

Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

T. Choueiri, D. McDermott, R. Perini, 2021, Journal of Clinical Oncology.

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies

A. Muehler, K. Venkatakrishnan, J. Nemunaitis, 2017, Investigational New Drugs.

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements

A. Drilon, D. Hong, S. Siena, 2015 .

Combination Regimens of Mirvetuximab Soravtansine, A Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, With Standard-Of-Care Agents Offer Promise for the Treatment of Ovarian Cancer

T. Bauer, 2017 .

Podcast on the Management of Adverse Events Associated with Lorlatinib

E. Bertino, T. Bauer, 2022, Advances in Therapy.

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Marie Evangelista, F. Peale, Yuan Chen, 2016, Clinical Cancer Research.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2019, Prostate Cancer and Prostatic Diseases.

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.

A. Shaw, S. Peters, E. Felip, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study

F. Janku, K. Papadopoulos, J. Bendell, 2015, Journal of Immunotherapy for Cancer.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

A. Drilon, A. Shaw, S. Ou, 2015 .

Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

A. Drilon, L. Bazhenova, B. Konda, 2021, Clinical Trials.

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors

M. Galsky, K. Yonemori, C. Chappey, 2022, JAMA oncology.

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

R. Plummer, U. Vaishampayan, Y. Ou, 2017, Experimental Hematology & Oncology.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

M. Ladanyi, M. Berger, A. Drilon, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.

A. Shaw, E. Felip, F. de Marinis, 2022, Lung cancer.

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

B. Solomon, J. Jassem, Geoffrey Liu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.

A. Shaw, T. Mok, Yi-long Wu, 2022, The Lancet. Respiratory medicine.

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Hong Wang, J. Wolchok, D. Davar, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

B. Tuch, J. Lee, A. Shaw, 2019 .

Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.

David C. Smith, E. Schmidt, V. Borges, 2017 .

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

G. Giaccone, P. Moore, R. Lechleider, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

L. Dirix, R. Carvajal, M. Peeters, 2021, Investigational New Drugs.

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy

G. Lesinski, T. Bekaii-Saab, W. Carson, 2011, Cancer Immunology, Immunotherapy.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

R. Govindan, R. Kruger, B. Besse, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

C. Schnell, D. Juric, J. Harding, 2018, Investigational New Drugs.

Signature program: a platform of basket trials

D. Berry, S. Stein, F. Meric-Bernstam, 2018, Oncotarget.

Targeting PI3 kinase in cancer.

J. Infante, T. Bauer, M. Patel, 2015, Pharmacology & therapeutics.

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

A. Drilon, A. Shaw, S. Ou, 2016 .

MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC: Topic: Medical Oncology

Dong-Wan Kim, M. Schuler, D. Hong, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2016 .

Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.

G. Giaccone, Y. Bang, H. Burris, 2013 .

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

P. Ott, K. Papadopoulos, J. Bendell, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

R. Neuwirth, G. Falchook, S. Chowdhury, 2018, ESMO Open.

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, Investigational new drugs.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

David C. Smith, E. Schmidt, A. Balmanoukian, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

E. Schmidt, A. Balmanoukian, S. Patel, 2017 .

Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, A. Balmanoukian, 2017 .

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

A. Shaw, S. Ou, Gregory Riely, 2018, The Lancet. Oncology.

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

R. Heist, K. Kelly, E. Vokes, 2021, Clinical Cancer Research.

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study

F. Meric-Bernstam, S. Piha-Paul, F. Braiteh, 2019, Oncotarget.

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

T. Wilson, H. Wildiers, Philippe Bédard, 2019, Breast Cancer Research and Treatment.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

C. Rudin, R. Govindan, Melissa L. Johnson, 2017, The Lancet. Oncology.

Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors

V. Keedy, T. Bauer, S. Y. Jung, 2019, Cancer Chemotherapy and Pharmacology.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

B. Tuch, J. Lee, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

A. Varghese, D. Hyman, J. Bendell, 2018, Clinical Cancer Research.

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

G. Naik, G. Shapiro, F. Meric-Bernstam, 2021, Clinical Cancer Research.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).

F. Meric-Bernstam, P. LoRusso, G. Schwartz, 2018 .

Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.

G. Shapiro, J. Infante, P. Bedard, 2017 .

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017 .

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.

A. Shaw, E. Felip, B. Solomon, 2015 .

A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors

J. Bendell, H. Burris, D. Spigel, 2016, Cancer investigation.

Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.

P. LoRusso, Z. Wainberg, A. Patnaik, 2019, Journal of Clinical Oncology.

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

M. Schuler, D. Hong, A. Delmonte, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

D. Nam, Y. Bang, M. Schuler, 2019, Cancer science.

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

A. Italiano, M. Chiron, Chia‐Chi Lin, 2022, Journal for ImmunoTherapy of Cancer.

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

R. Heist, K. Kelly, E. Vokes, 2021, JTO clinical and research reports.

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

A. Drilon, T. Choueiri, M. Voss, 2019, Clinical Cancer Research.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

D. Faller, Carrie Lee, A. Lockhart, 2018, Investigational new drugs.

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine

A. Oza, M. Birrer, U. Matulonis, 2018, Clinical Cancer Research.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).

B. Linghu, C. Drake, J. Bendell, 2020 .

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

J. Hecht, Z. Wainberg, K. Papadopoulos, 2020, Investigational New Drugs.

Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.

H. Hurwitz, C. Ock, J. Clarke, 2018 .

Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.

M. Gordon, D. Wong, T. Bauer, 2021, Clinical lung cancer.

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.

E. Smit, Yi-long Wu, T. Bauer, 2021, Cancer treatment reviews.

1214OEpacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037

E. Schmidt, A. Balmanoukian, A. Frankel, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

P. LoRusso, G. Schwartz, M. Gounder, 2020 .

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

A. Drilon, B. Tuch, T. Mok, 2018, Journal of Thoracic Oncology.

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

A. Drilon, Keunchil Park, Melissa L. Johnson, 2018 .

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

David C. Smith, D. Kaufman, A. Balmanoukian, 2015, Journal of Immunotherapy for Cancer.

A phase I study of MEDI6383, an OX40 agonist, in adult patients with select advanced solid tumors.

J. Norton, S. Patel, Y. Chae, 2015 .

High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).

R. Emerson, G. Giaccone, E. Rock, 2019, Journal of Clinical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

J. Schellens, M. Millward, M. Maio, 2017 .

Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.

J. Gregg, J. Hughes, V. Miller, 2019, Journal of gastrointestinal oncology.

Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy

P. Philip, A. Shields, Xiaobai Li, 2013, Cancer.

1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma

M. Gounder, N. Yamamoto, T. Bauer, 2021, Annals of Oncology.

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

David C. Smith, D. Kaufman, A. Balmanoukian, 2016 .

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

R. Heist, B. C. Cho, Dong-Wan Kim, 2022, Investigational New Drugs.

Clinical Management of Adverse Events Associated with Lorlatinib.

A. Shaw, E. Felip, B. Solomon, 2019, The oncologist.

Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).

R. Srinivasan, M. Voss, G. Shapiro, 2018 .

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.

R. Srinivasan, M. Voss, A. DeMichele, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.

R. Figlin, T. Choueiri, M. Michaelson, 2023, The Lancet. Oncology.

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

R. Sullivan, A. Jimeno, P. LoRusso, 2020 .

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

E. Schmidt, J. Schellens, A. Hansen, 2023, Journal for ImmunoTherapy of Cancer.

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

L. Chow, J. Infante, L. Siu, 2016 .

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

R. Doebele, G. Schwartz, M. Gounder, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

Benjamin Solomon, A. Shaw, E. Felip, 2016 .

Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.

R. Greil, A. Santoro, T. Yau, 2021 .

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

A. Shaw, S. Ou, Gregory Riely, 2019, The Lancet. Oncology.

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

H. Hurwitz, T. George, Yining Du, 2018, OncoTargets and therapy.

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay

A. Grothey, S. Kopetz, Z. Wainberg, 2019, JCO precision oncology.

Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2018, Clinical Trials.

Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

D. Chakrabarti, A. Shaw, E. Felip, 2018 .

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

D. Faller, Carrie Lee, A. Lockhart, 2018, Investigational new drugs.

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors.

K. Papadopoulos, M. Bennett, S. Fu, 2017 .

CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

R. Srinivasan, M. Voss, G. Shapiro, 2019, Journal of Clinical Oncology.

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of Clinical Oncology.

Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

M. Birrer, H. Borghaei, U. Matulonis, 2017, Cancer.

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Suzanne F. Jones, D. V. Von Hoff, G. Weiss, 2014, European journal of cancer.

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.

M. Lowery, A. Varghese, P. Klein, 2017 .

OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer

A. Shaw, S. Ou, E. Felip, 2017 .

ORAL02.01: Safety and Efficacy of Single‐Agent Rovalpituzumab Tesirine, a DLL3‐Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology

C. Rudin, R. Govindan, L. Byers, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.

A. Shaw, S. Ou, E. Felip, 2017 .

Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.

Suzanne F. Jones, G. Giaccone, Y. Bang, 2015 .

Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours

K. Papadopoulos, A. Fasolo, A. Naing, 2019, Annals of Oncology.

Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, V. Borges, 2017 .

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.

C. Chappey, D. Hyman, T. Yap, 2019, Journal of Clinical Oncology.

A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.

E. Jonasch, K. Papadopoulos, Keshi Wang, 2018 .

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy

J. Reeves, I. Flinn, J. Essell, 2017, British journal of haematology.

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

M. Birrer, U. Matulonis, R. Perez, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A 17 Year-Old Man with an Exon 11 Mutation of CD-117 Causing a Gastrointestinal Stromal Tumor

J. Berlin, T. Bauer, 2008, Cancer investigation.

656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)

T. Choueiri, D. McDermott, R. Perini, 2021, Annals of Oncology.

547P Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131)

G. Shapiro, T. Yap, R. Jeselsohn, 2020 .

OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases

A. Drilon, B. Tuch, V. Velcheti, 2017 .

Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors

F. Peale, Yuan Chen, P. LoRusso, 2015 .

LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

A. Shaw, T. Mok, E. Felip, 2020 .

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

C. Kyriakopoulos, D. Potvin, J. Christensen, 2018 .

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

P. Ascierto, J. Kirkwood, A. Shoushtari, 2023, Journal for ImmunoTherapy of Cancer.

MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC

A. Shaw, T. Mok, E. Felip, 2021 .

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

A. Muehler, K. Venkatakrishnan, J. Nemunaitis, 2014, Investigational New Drugs.

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

G. Fabbri, H. Edlund, K. Sachsenmeier, 2019, Journal of Clinical Oncology.

A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.

Suzanne F. Jones, J. Barrett, Melissa L. Johnson, 2016 .

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program.

K. Kelly, L. Nadauld, J. Grilley-Olson, 2016 .

Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.

E. Lam, B. Somer, N. Vogelzang, 2019, Journal of Clinical Oncology.

Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts

Suzanne F. Jones, A. Tinker, A. Oza, 2019, Clinical Trials.

Abstract CT210: A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral injection alone and in combination with immune checkpoint blockade

A. Jimeno, J. Frederick, T. Zaks, 2019, Clinical Trials.

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Suzanne F. Jones, A. Tinker, A. Oza, 2023, Targeted Oncology.

Abstract C087: Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor

S. Leong, Ying Su, R. Ruiz-Soto, 2019 .

Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.

A. Oza, M. Birrer, U. Matulonis, 2017 .

The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

M. Teufel, M. Gounder, T. Bauer, 2023, Cancer discovery.

Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)

A. Drilon, J. Wolf, B. Besse, 2020, Pneumologie.

Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.

M. Birrer, P. LoRusso, H. Borghaei, 2014 .

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

C. Drake, J. Bendell, D. George, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

E. Jonasch, T. Choueiri, M. Michaelson, 2019, Annals of Oncology.

The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.

E. Jonasch, T. Choueiri, M. Michaelson, 2021 .

Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).

E. Jonasch, T. Choueiri, M. Michaelson, 2020 .

Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.

Suzanne F. Jones, F. Meric-Bernstam, J. Bendell, 2015 .

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Manish B. Patel, A. Iafrate, A. Drilon, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer

A. Shaw, B. Solomon, J. Martini, 2018, Journal of Thoracic Oncology.

Phase 1 study of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

A. Oza, M. Birrer, H. Borghaei, 2015 .

Preliminary single agent activity of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

A. Oza, M. Birrer, R. Perez, 2015 .

Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted therapies.

P. LoRusso, J. Eder, G. Falchook, 2016 .

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.

L. Appleman, A. Roy, T. Bauer, 2023, European journal of cancer.

Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.

P. LoRusso, C. Brooks, E. Chiorean, 2018 .